Literature DB >> 22872156

Genetic variants that affect platelet function.

Thomas J Kunicki1, Shirley A Williams, Diane J Nugent.   

Abstract

PURPOSE OF REVIEW: This review summarizes our current knowledge of common gene variants (polymorphisms) that have small individual effects on platelet function in humans, but can cumulatively lead to hyperreactive platelets and increase risk for negative outcomes in thrombotic disorders. RECENT
FINDINGS: Candidate gene association and genome-wide association studies (GWAS) have identified loci that include single nucleotide polymorphisms, which exert a cumulative effect on platelet function by modifying basic platelet parameters, such as mean platelet volume (MPV) or platelet count, by altering the expression or activity of key platelet receptors, or by influencing downstream effector pathways utilized by these receptors.
SUMMARY: Variation in MPV between normal individuals is responsible for roughly a two-fold range in platelet protein content, including key surface receptors and reactive granule constituents, the association of ADRA2, GP1BA, GP6, ITGA2 and P2Y12 variants with platelet reactivity, initially identified by candidate gene analyses, has now been validated by genome-wide approaches in much larger individual cohorts, and GWAS have identified novel gene variants, most notably PEAR1, that participate in variation in platelet reactivity among normal individuals, all of which contribute to a genetic basis for differences in platelet reactivty among normal individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872156     DOI: 10.1097/MOH.0b013e3283567526

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  18 in total

Review 1.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

Review 2.  A tour through the transcriptional landscape of platelets.

Authors:  Sebastian Schubert; Andrew S Weyrich; Jesse W Rowley
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

Review 3.  Antiplatelet therapy: targeting the TxA2 pathway.

Authors:  P Fontana; A Zufferey; Y Daali; J-L Reny
Journal:  J Cardiovasc Transl Res       Date:  2013-12-19       Impact factor: 4.132

Review 4.  Glanzmann thrombasthenia: state of the art and future directions.

Authors:  Alan T Nurden; Xavier Pillois; David A Wilcox
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

5.  Identification of mutations in SLC4A1, GP1BA and HFE in a family with venous thrombosis of unknown cause by next-generation sequencing.

Authors:  Wei-An Chang; Chau-Chyun Sheu; Kuan-Ting Liu; Jheng-Heng Shen; Meng-Chi Yen; Po-Lin Kuo
Journal:  Exp Ther Med       Date:  2018-09-04       Impact factor: 2.447

Review 6.  Rare platelet GPCR variants: what can we learn?

Authors:  S P Nisar; M L Jones; M R Cunningham; A D Mumford; S J Mundell
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

7.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

8.  Conditional knockout of integrin α2β1 in murine megakaryocytes leads to reduced mean platelet volume.

Authors:  David Habart; Yann Cheli; Diane J Nugent; Zaverio M Ruggeri; Thomas J Kunicki
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome.

Authors:  Eric R Londin; Eleftheria Hatzimichael; Phillipe Loher; Leonard Edelstein; Chad Shaw; Kathleen Delgrosso; Paolo Fortina; Paul F Bray; Steven E McKenzie; Isidore Rigoutsos
Journal:  Biol Direct       Date:  2014-02-14       Impact factor: 4.540

10.  Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study.

Authors:  Hilde Jensvoll; Kristine Blix; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.